Phase 3 Asthma Trial, Recruiting NCT06829784 Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Condition: Asthma
Back to Asthma

Phase 3 Asthma Trial, Recruiting

NCT06829784
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign a consent form showing they understand the trial's purpose, process, and possible side effects before it begins
  • People aged between 18 and 75 years old (any gender)
  • People who have had a formal asthma diagnosis from a doctor for at least 12 months before the first trial visit
  • People who have been prescribed high-dose inhaled corticosteroids (a type of asthma preventer medication) for at least 6 months before the first trial visit
  • People who have been on a stable daily dose of their inhaled corticosteroid for at least 3 months before the first trial visit
  • People who have been taking any other asthma control medications at a stable dose for at least 3 months before the first trial visit; for those also taking oral steroid tablets, the dose must be no more than 10mg of prednisone (or equivalent) per day, and must have been stable for at least 30 days before the first visit
  • People who have had at least 2 asthma flare-ups in the 12 months before the first trial visit, with no major flare-up in the month before signing the consent form

Who may not be able to join:

  • People who have a significant lung condition other than asthma
  • People who have a pre-existing autoimmune disease (where the immune system attacks the body)
  • People with a history of a weakened immune system or serious infections linked to immune problems
  • People with any other medical condition that the trial doctor does not consider to be stable
  • People with a history of most cancers, unless a curative treatment for certain limited skin cancers or cervical cancer in situ was completed at least 12 months before the first visit, or curative treatment for other cancers was completed at least 5 years before the first visit (confirm with trial site)
  • People who currently smoke, or who have a smoking history of 10 or more pack-years; former smokers with less than 10 pack-years of smoking history who quit less than 6 months before the first visit may also not be eligible (confirm with trial site)
  • People whom the trial doctor determines are not suitable to participate for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 18928868238

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Registry
ClinicalTrials.gov
Start date
21 March 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Annualized incidence of asthma exacerbations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov